PROS1 and prostate carcinoma: Patients without pathological findings (n = 37; Table 2) had a median PSA of 0.30 ng/ml (range 0.13–3.24), a PSA doubling time of mainly ≤10 months (67.6%), mainly a T3 N0 prostate cancer and a predominant GS 7b.